Autosomal-dominant polycystic kidney disease (ADPKD) affects up to 12 million individuals
and is the fourth most common cause for renal replacement therapy worldwide. There have …

There is increasing international attention in efforts to integrate palliative care principles,
including pain and symptom management, into the care of patients with advanced chronic …

There are an estimated 14,000 randomized trials published in chronic kidney disease. The
most frequently reported outcomes are biochemical endpoints, rather than clinical and …

Pain is a major health problem in end-stage renal disease (ESRD) affecting half of the
dialysis patients; most of them experience a moderate to severe degree of pain …

Background In people with early autosomal dominant polycystic kidney disease (ADPKD),
average total kidney volume (TKV) is 3 times normal and increases by an average of 5% per …

The natural history of autosomal dominant polycystic kidney disease (ADPKD) is
characterized by a variable rate of cyst development and increase in total kidney volume …

The present review summarized the current advances and novel research on minimal
invasive techniques for musculoskeletal disorders. Different invasive approaches were …

Polycystic kidney disease (PKD) is a multiorgan disorder resulting in fluid-filled cyst
formation in the kidneys and other systems. The replacement of kidney parenchyma with an …

Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive
polycystic kidney disease (ARPKD) are important inherited kidney diseases with distinct …

Background Kidney pain is a common complication in patients with autosomal dominant
polycystic kidney disease (ADPKD), and data from the TEMPO 3: 4 trial suggested that …